Chaudhari 2001.

Study characteristics
Methods	RCT, placebo‐controlled, double‐blind Date of study: not stated Location: single centre, New Jersey, USA
Participants	Randomised: 33 participants (age mean 35 years (infliximab 10), 51 years (infliximab 5), 45 years (placebo), 23 male) Inclusion criteria Participants with moderate‐severe psoriasis (BSA ≥ 5) Non‐response to topical treatment Exclusion criteria Immunosuppression Had received biologics Had an active infection Had past history of malignant tumours Dropouts and withdrawals 3/33 (9%) Time and reasons: worsening psoriasis (n = 1 from infliximab 10 mg/kg group), mild rash (n = 1 from infliximab 5 mg/kg group), lack improvement disease (n = 1 from placebo group)
Interventions	Intervention A. Infliximab (n = 11), IV, 5 mg/kg, weeks 0, 2, 6, 10 Control intervention B. Infliximab (n = 11), IV, 10 mg/kg, weeks 0, 2, 6, 10 C. Placebo (n = 11), IV, 20 mL, weeks 0, 2, 6, 10
Outcomes	Assessment at 10 weeks Primary outcomes of the trial PGA good, excellent or clear Secondary outcomes of the trial PASI 75
Notes	Funding: Y Johnson and Johnson, Centocor Inc Declarations of interest: not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote (p 1843): "...were randomly assigned... by means of a lock‐of‐six randomisation scheme" Comment: probably done
Allocation concealment (selection bias)	Unclear risk	Comment: no description of the method used to guarantee allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote (p 1843): "Placebo was supplied in a identical manner except that it did not contain IFX...The infliximab infusion solution was given by investigators unaware of treatment assignment..." Comment: probably done
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote (p 1843): "All assessments were done in a masked manner" Comment: probably done
Incomplete outcome data (attrition bias) All outcomes	Low risk	Randomly assigned 33, analysed 33 Dropouts and withdrawals 3/33 (9%) Time and reasons: worsening psoriasis (n = 1 from infliximab 10 mg/kg group), mild rash (n = 1 from infliximab 5 mg/kg group), lack improvement disease (n = 1 from placebo group) Management of missing data: Quote (p 1844): "The primary analysis was done according to ITT, all randomised patients were included" Comment: probably done
Selective reporting (reporting bias)	Unclear risk	Comment: no protocol was available. The prespecified outcomes mentioned in the Methods section appeared to have been reported